Alternate-day treatment with crizotinib for drug-induced esophagitis and liver damage in a patient with EML4-ALK fusion gene-positive lung adenocarcinoma

Yoko Tsukita, Tatsuro Fukuhara, Maki Kobayashi, Mami Morita, Aya Suzuki, Kana Watanabe, Tetsuya Noguchi, Yasuko Kurata, Manabu Suno, Makoto Maemondo

研究成果: Article

4 引用 (Scopus)

抜粋

A 44-year-old woman who was diagnosed with anaplastic lymphoma kinase-positive lung adenocarcinoma developed brain metastases, multiple spinal metastases and meningeal dissemination. Crizotinib was administered after the failure of first-line chemotherapy. Esophagitis and liver damage were induced by the twicedaily administration of crizotinib at 250 mg and 200 mg, respectively. The alternate-day administration of crizotinib (250 mg, twice daily) was able to control disease progression without any adverse effects for several months. We evaluated the relationship between the serum concentration of crizotinib and the development of esophagitis and liver damage. The alternate-day administration of crizotinib is one of the strategies for managing the severe toxicity of crizotinib.

元の言語English
ページ(範囲)3185-3188
ページ数4
ジャーナルInternal Medicine
54
発行部数24
DOI
出版物ステータスPublished - 2015 12 15
外部発表Yes

ASJC Scopus subject areas

  • Internal Medicine

フィンガープリント Alternate-day treatment with crizotinib for drug-induced esophagitis and liver damage in a patient with EML4-ALK fusion gene-positive lung adenocarcinoma' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用